stockportfolio.pro
Halozyme Therapeutics, Inc. P/E Ratio 2009–2025
Halozyme Therapeutics, Inc. (HALO) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -3.3%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 26.29 | +88.6% |
| FY 2024 | 13.94 | -20.8% |
| FY 2023 | 17.60 | -55.5% |
| FY 2022 | 39.51 | +169.3% |
| FY 2021 | 14.68 | -68.7% |
| FY 2020 | 46.93 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | 45.02 | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Halozyme Therapeutics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s price-to-earnings ratio?
Halozyme Therapeutics, Inc. (HALO) reported price-to-earnings ratio of 26.29 for fiscal year 2025, per its SEC filings.
How has Halozyme Therapeutics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, HALO's price-to-earnings ratio declined at roughly 3.3% per year (compound annual rate), from 45.02 to 26.29.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.